T1	Participants 64 125	hospitalized patients with lower respiratory tract infections
T2	Participants 272 284	121 patients
T3	Participants 298 326	92 were clinically evaluable
T4	Participants 338 377	59 patients were treated with ofloxacin
T5	Participants 382 409	33 with the comparator drug
